SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-93451"
 

Sökning: id:"swepub:oai:DiVA.org:oru-93451" > Discordance of PD-L...

  • Boman, CarolineKarolinska Institutet (författare)

Discordance of PD-L1 status between primary and metastatic breast cancer : A systematic review and meta-analysis

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • Elsevier,2021
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-93451
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-93451URI
  • https://doi.org/10.1016/j.ctrv.2021.102257DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147536725URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:for swepub-publicationtype

Anmärkningar

  • INTRODUCTION: Programmed cell death ligand 1 (PD-L1) expression is predictive for benefit from immunotherapy in several human malignancies including triple negative breast cancer. Lower positivity rates but a larger relative benefit from atezolizumab has been implied when PD-L1 status is assessed at metastatic sites. We aimed to study the discordance of PD-L1 expression between primary tumor and metastasis in breast cancer due to its potential clinical utility.METHODS: Cochrane Library, Embase, Medline and Web of science were searched for studies reporting on PD-L1 expression in primary and metastatic breast cancer, followed by data extraction. Outcomes included pooled PD-L1 positivity rates in tumor cells, immune cells or both in primary tumor and metastasis, PD-L1 discordance between matched primary tumors and metastasis and direction of discordance.RESULTS: Of 2552 identified entries following de-duplication, 20 studies fulfilled the predefined inclusion criteria. Pooled PD-L1 positivity rate was higher in primary tumors compared to metastasis when assessed in immune cells (51.2% vs 37.1% p < 0.001) and tumor/immune cells (30.1% vs 14.6% p < 0.001), but not in tumor cells (18.7% vs 17.8% p = 0.65). PD-L1 positivity was lowest when assessed in bone metastases (12%) and highest in lymph nodes (60%). Discordance between primary tumors and metastasis was bidirectional, with higher pooled discordance rates when PD-L1 expression was assessed in immune compared to tumor cells (39.5% vs 13.6%, p < 0.001).CONCLUSION: The observed considerable discordance between PD-L1 status in primary and metastatic breast cancer emphasizes the importance of appropriate tissue sampling when selecting patients for immunotherapy.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Zerdes, IoannisKarolinska Institutet (författare)
  • Mårtensson, KiraDepartment of Clinical Pathology and Cytology, Karolinska University Laboratory, Stockholm, Sweden (författare)
  • Bergh, JonasKarolinska Institutet (författare)
  • Foukakis, TheodorosKarolinska Institutet (författare)
  • Valachis, Antonis,1984-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology(Swepub:oru)asvs (författare)
  • Matikas, AlexiosKarolinska Institutet (författare)
  • Karolinska InstitutetDepartment of Clinical Pathology and Cytology, Karolinska University Laboratory, Stockholm, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Cancer Treatment Reviews: Elsevier990305-73721532-1967

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy